NL-OMON51427尚未招募2 期
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy - 232SM203 (Devote)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 1(—)
入选标准
- •- Genetic documentation of 5q SMA (homozygous gene deletion, mutation, or
- •compound heterozygote)
- •- Participants with SMA symptom onset <= 6 months (<= 180 days) of age (infantile
- •onset) should have age > 1 week to <= 7 months (<= 210 days) at the time of
- •informed consent
- •- Participants with SMA symptom onset > 6 months (> 180 days) of age (later
- •- Age 2 to < 10 years at the time of informed consent
- •- Can sit independently but has never had the ability to walk independently
- •- HFMSE score >= 10 and <= 54 at Screening
排除标准
- •- Presence of an untreated or inadequately treated active infection requiring
- •systemic antiviral or antimicrobial therapy at any time during the Screening
- •- Presence of an implanted shunt for the drainage of CSF or of an implanted
- •central nervous system (CNS) catheter
- •- Hospitalization for surgery, pulmonary event, or nutritional support within 2
- •months prior to Screening or planned within 12 months after the participant's
- •- Treatment with an investigational drug including but not limited to the
- •treatment of SMA, biological agent, or device within 30 days or 5 half-lives of
- •the agent, whichever is longer, prior to Screening or anytime during the study;
- •any prior or current treatment with any survival motor neuron-2 (SMN2)-
- •splicing modifier or gene therapy; or prior antisense oligonucleotide
- •treatment, or cell transplantation
- •- Participants with SMA symptom onset > 6 months (> 180 days) of age (later
- •- Respiratory insufficiency, defined by the medical necessity for invasive or
- •noninvasive ventilation for > 6 hours during a 24-hour period, at Screening
- •- Medical necessity for a gastric feeding tube
- •- Participants with SMA symptom onset <= 6 months (<= 180 days) of age (infantile
- •onset): Signs or symptoms of SMA present at birth or within the first week
- •after birth
研究者
相似试验
进行中(未招募)
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-HUBiogen Idec Research Limited100
尚未招募
2 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy Muscular Atrophy, Spinal Atrophy Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Spinal Cord Diseases Central Nervous System Diseases Motor Neuron Disease Neurodegenerative Diseases Neuromuscular DiseasesG12.9Spinal Muscular AtrophyLBCTR2021064778Biogen Idec Research Limited2
进行中(未招募)
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-FRBiogen Idec Research Limited152
进行中(未招募)
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-ITBIOGEN IDEC RESEARCH LIMITED152
进行中(未招募)
1 期
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002663-10-LVBiogen Idec Research Limited100
